Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 3, 2008, Pages 209-217

  Someya, Yuka ^a   Tahara, Atsuo ^a   Nakano, Ryosuke ^a   Matsuyama Yokono, Akiko ^a   Nagase, Itsuro ^a   Fukunaga, Yasuhisa ^a   Takasu, Toshiyuki ^a   Hayakawa, Masahiko ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

ASP8497; Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1

Indexed keywords

[4 FLUORO 1 [[[4 METHYL 1 (METHYLSULFONYL)PIPERIDIN 4 YL]AMINO]ACETYL]PYRROLIDINE 2 CARBONITRILE MONOFUMARATE]; ASP 8497; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PROLINE; PROTEINASE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG DISTRIBUTION; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; RODENT; ZUCKER RAT;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDASES; DIPEPTIDYL PEPTIDASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; INSULIN; MALE; MICE; MICE, INBRED ICR; PIPERIDINES; PROTEASE INHIBITORS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

EID: 42449092800     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-008-0277-8     Document Type: Article

References (27)

1. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD (2000) Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267:6140-6150
2. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
3. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
4. Ajami K, Abbott CA, McCaughan GW, Gorrell MD (2004) Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 1679:18-28
5. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:5025-5037
6. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
7. Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Eagtmann N, Rasmussen HB (2006) Dipeptidyl peptidase 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 396:391-399
8. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR (2005) Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315:688-695
9. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
10. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408
11. Holst JJ, Deacon CF (2004) Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 4:589-596
12. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
13. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4, 3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151
14. Knudsen LB (2004) Glucagon-like peptide-1: the bases of a new class of treatment for type 2 diabetes. J Med Chem 47:4128-4134
15. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes 54:2988-2994
16. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT, Thornberry NA (2003) Catalytic properties and inhibition of proline-specific dipeptidyl peptidase II, IV and VII. Biochem J 371:525-532
17. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB (2002) The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51(Suppl. 3):S434-S442
18. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24
19. Panten U, Schwanstecher M, Schwanstecher C (1992) Pancreatic and extrapancreatic sulfonylurea receptors. Horm Metab Res 24:549-554
20. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274:36505-36512
21. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, Sitagliptin Study 023 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564-2571
22. Ristic S, Byiers S, Foley J, Holmes D (2005) Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 7:692-698
23. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A (2007) Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30:217-223
24. Stahl M, Berger W (1999) Higher incidence of severe hypoglycemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 16:586-590
25. Takasaki K, Iwase M, Nakajima T, Ueno K, Nomoto Y, Nakanishi S, Higo K (2004) K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur J Pharmacol 486:335-342
26. Taylor SI, Accili D, Imai Y (1994) Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 43:735-740
27. Underwood R, Chiravuri H, Lee H, Schmitz T, Kabcenell AK, Yardley K, Huber BT (1999) Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 274:34053-34058